Clarametyx Biosciences, Inc.

[Available On-Demand]
Clarametyx Biosciences is building a transformative biologic platform for biofilm-associated disease. Our fundamentally new category of non-antibiotic, pro-stewardship therapies and vaccines enables innate immune response and first line antibiotic efficacy against persistent infections. Clarametyx is led by veteran sector-relevant management and scientific experts, and is CARB-X funded for its lead CMTX-101 therapeutic monoclonal antibody for up to approximately $14.3 million though Phase 1.
Company Type:
Company Website:
Company HQ State:
Ohio
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
CMTX-101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Clarametyx Biosciences